Hart A Goldhar1, Andrew T Yan1, Dennis T Ko1, Craig C Earle1, George A Tomlinson1, Maureen E Trudeau1, Murray D Krahn1, Monika K Krzyzanowska1, Raveen S Pal1, Christine Brezden-Masley1, Scott Gavura1, Kelly Lien1, Kelvin K W Chan2. 1. : Faculty of Medicine, University of Toronto, Toronto, ON (HAG, ATY, DTK, CCE, GAT, MET, MDK, MKK, CB, KKWC); Division of Cardiology, St. Michael's Hospital, Toronto, ON (ATY); Institute for Clinical Evaluative Sciences, Toronto, ON (DTK, CCE, MKK); Schulich Heart Centre, Sunnybrook Health Sciences Centre, Toronto, ON (DTK); Division of Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, ON (CCE, MET, KL, KKWC); Ontario Institute for Cancer Research, Toronto, ON (CCE); University Health Network, Toronto, ON (GAT, MKK); Toronto Health Economics and Health Assessment, Toronto, ON (MDK); Division of Hematology/Oncology, St. Michael's Hospital, Toronto, ON (CB); Department of Medicine, Queens University, and Cardiac Program, Kingston General Hospital, Kingston, ON (RSP); Cancer Care Ontario, Toronto, ON (SG). 2. : Faculty of Medicine, University of Toronto, Toronto, ON (HAG, ATY, DTK, CCE, GAT, MET, MDK, MKK, CB, KKWC); Division of Cardiology, St. Michael's Hospital, Toronto, ON (ATY); Institute for Clinical Evaluative Sciences, Toronto, ON (DTK, CCE, MKK); Schulich Heart Centre, Sunnybrook Health Sciences Centre, Toronto, ON (DTK); Division of Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, ON (CCE, MET, KL, KKWC); Ontario Institute for Cancer Research, Toronto, ON (CCE); University Health Network, Toronto, ON (GAT, MKK); Toronto Health Economics and Health Assessment, Toronto, ON (MDK); Division of Hematology/Oncology, St. Michael's Hospital, Toronto, ON (CB); Department of Medicine, Queens University, and Cardiac Program, Kingston General Hospital, Kingston, ON (RSP); Cancer Care Ontario, Toronto, ON (SG). kelvin.chan@sunnybrook.ca.
Abstract
BACKGROUND: The late cardiac effect of adjuvant trastuzumab and its potential interaction with anthracycline have not been well-studied on a population level. METHODS: In this retrospective population-based cohort study, female breast cancer patients in Ontario, diagnosed between 2003 and 2009, were identified by the Ontario Cancer Registry and linked to administrative databases to ascertain demographics, cardiac risk factors, comorbidities, and use of adjuvant trastuzumab and other chemotherapy. Patients with pre-existing heart failure (HF) were excluded. The main endpoint was new diagnosis of HF. Analyses included Kaplan-Meier (KM) survival analysis, multivariable piecewise Cox regression, and competing risk and propensity score analyses. All statistical tests were two-sided. RESULTS: Nineteen thousand seventy-four women with breast cancer treated with adjuvant chemotherapy were identified, of whom 3371 (17.7%) also received adjuvant trastuzumab. Anthracycline use was 84.9% overall. After a median follow-up of 5.9 years, patients treated with trastuzumab and chemotherapy were more likely to develop HF than patients on chemotherapy alone (5-year cumulative incidences of 5.2% vs 2.5%; log-rank P < .001). After adjusting for confounders, adjuvant trastuzumab remained independently associated with incident HF in the first 1.5 years (HR = 5.77, 95% CI = 4.38 to 7.62, P < .001), but not thereafter (HR = 0.87, 95% CI = 0.57 to 1.33, P = .53). Anthracycline use did not increase the risk of HF with trastuzumab synergistically, neither within (P interaction = .92) nor beyond 1.5 years (P interaction = .23). CONCLUSION: Adjuvant trastuzumab was associated with increased risk of new incidence of HF in breast cancer survivors during the period of adjuvant treatment but not thereafter. Routine intensive monitoring may not be necessary after completing adjuvant therapy.
BACKGROUND: The late cardiac effect of adjuvant trastuzumab and its potential interaction with anthracycline have not been well-studied on a population level. METHODS: In this retrospective population-based cohort study, female breast cancerpatients in Ontario, diagnosed between 2003 and 2009, were identified by the Ontario Cancer Registry and linked to administrative databases to ascertain demographics, cardiac risk factors, comorbidities, and use of adjuvant trastuzumab and other chemotherapy. Patients with pre-existing heart failure (HF) were excluded. The main endpoint was new diagnosis of HF. Analyses included Kaplan-Meier (KM) survival analysis, multivariable piecewise Cox regression, and competing risk and propensity score analyses. All statistical tests were two-sided. RESULTS: Nineteen thousand seventy-four women with breast cancer treated with adjuvant chemotherapy were identified, of whom 3371 (17.7%) also received adjuvant trastuzumab. Anthracycline use was 84.9% overall. After a median follow-up of 5.9 years, patients treated with trastuzumab and chemotherapy were more likely to develop HF than patients on chemotherapy alone (5-year cumulative incidences of 5.2% vs 2.5%; log-rank P < .001). After adjusting for confounders, adjuvant trastuzumab remained independently associated with incident HF in the first 1.5 years (HR = 5.77, 95% CI = 4.38 to 7.62, P < .001), but not thereafter (HR = 0.87, 95% CI = 0.57 to 1.33, P = .53). Anthracycline use did not increase the risk of HF with trastuzumab synergistically, neither within (P interaction = .92) nor beyond 1.5 years (P interaction = .23). CONCLUSION: Adjuvant trastuzumab was associated with increased risk of new incidence of HF in breast cancer survivors during the period of adjuvant treatment but not thereafter. Routine intensive monitoring may not be necessary after completing adjuvant therapy.
Authors: Heikki Joensuu; Judith Fraser; Hans Wildiers; Riikka Huovinen; Päivi Auvinen; Meri Utriainen; Paul Nyandoto; Kenneth K Villman; Päivi Halonen; Helena Granstam-Björneklett; Lotta Lundgren; Liisa Sailas; Taina Turpeenniemi-Hujanen; Minna Tanner; Jeffrey Yachnin; Diana Ritchie; Oskar Johansson; Teppo Huttunen; Patrick Neven; Peter Canney; Vernon J Harvey; Pirkko-Liisa Kellokumpu-Lehtinen; Henrik Lindman Journal: JAMA Oncol Date: 2018-09-01 Impact factor: 31.777
Authors: Vinita Dhir; Andrew T Yan; Rosane Nisenbaum; Joanna Sloninko; Kim A Connelly; Joseph Barfett; Rashida Haq; Anish Kirpalani; Kelvin K W Chan; Teresa M Petrella; Christine Brezden-Masley Journal: Int J Cardiovasc Imaging Date: 2019-06-13 Impact factor: 2.357
Authors: L Masucci; S Torres; A Eisen; M Trudeau; I Tyono; H Saunders; K W Chan; W Isaranuwatchai Journal: Curr Oncol Date: 2019-10-01 Impact factor: 3.677
Authors: Peggy M Kostakou; Nikos T Kouris; Vassilios S Kostopoulos; Dimitrios S Damaskos; Christoforos D Olympios Journal: Heart Fail Rev Date: 2019-01 Impact factor: 4.214
Authors: C C Barron; M M Alhussein; U Kaur; T L Cosman; N K Tyagi; M Brown; S D Mukherjee; P M Ellis; S Dhesy-Thind; D P Leong Journal: Curr Oncol Date: 2019-08-01 Impact factor: 3.677
Authors: Peiqiang Yi; Huan Li; Yuehua Fang; Jun Su; Cheng Xu; Lu Cao; Min Li; Jiayi Chen Journal: Am J Cancer Res Date: 2020-02-01 Impact factor: 6.166
Authors: Vikram Jairam; Victor Lee; Henry S Park; Charles R Thomas; Edward R Melnick; Cary P Gross; Carolyn J Presley; Kerin B Adelson; James B Yu Journal: JAMA Oncol Date: 2019-07-01 Impact factor: 31.777